172 results on '"Downey, D.G."'
Search Results
2. Building global development strategies for cf therapeutics during a transitional cftr modulator era
3. P253 Optimisation of inhaled antibiotic prescribing for Pseudomonas aeruginosa infections in people with cystic fibrosis: Further insights from Principal Investigators of the ECFS Clinical Trials Network
4. P228 In vitro evolution of levofloxacin resistance in lineages of clinical Pseudomonas aeruginosa isolates cultured at different stages of infection from people with cystic fibrosis
5. EPS9.06 Development of levofloxacin resistance in clinical Pseudomonas aeruginosa isolates from people with cystic fibrosis in an in vitro variable exposure model
6. P115 Comparison of total bacterial and Pseudomonas aeruginosa load during PEx between infrequent and frequent exacerbators
7. P150 Antimicrobial prescribing in people with cystic fibrosis: exploring inhaled antibiotic use for Pseudomonas aeruginosa infections across the ECFS-CTN
8. ePS3.05 Induced levofloxacin resistance persists in evolved lineages of Pseudomonas aeruginosa isolates from people with cystic fibrosis after exposure to other inhaled antibiotics
9. Thoracic ultrasound for pleural effusion: Delays and cost associated with departmental scanning
10. P039 The clinical impact of triple CFTR modulator therapy in a cohort of people with cystic fibrosis and severe lung disease
11. P116 Clinical characteristics of frequent and infrequent pulmonary exacerbations
12. P149 Evolution of levofloxacin resistance and phenotypic characterisation of Pseudomonas aeruginosa clinical isolates from people with cystic fibrosis
13. P149 A review of the clinical trajectory of adults with cystic fibrosis prescribed nebulised Aztreonam Lysine (Cayston™)
14. P304 A questionnaire to assess views, practices and barriers to physical activity in adults with cystic fibrosis
15. P108 Chronic co-infection with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis is associated with accelerated decline in lung function
16. WS03.3 A review of ursodeoxycholic acid prescribing in an adult cystic fibrosis population
17. P353 “There’s no place like home”: formalising the provision of home IV antibiotics for people with cystic fibrosis in Northern Ireland
18. P197 The effect of ivacaftor on clinical trajectory of adults with cystic fibrosis carrying a R117H mutation
19. Neutrophils in cystic fibrosis
20. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis
21. Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis
22. P179 Detection of multi-drug resistant (MDR) Pseudomonas aeruginosa (PA) in people with cystic fibrosis
23. P453 An eight-year retrospective audit of clinical psychology referrals within the Northern Ireland Regional Adult Cystic Fibrosis Centre
24. P206 Does adherence to DNase change following initiation of Orkambi for the treatment of cystic fibrosis?
25. P247 Use of the Fitbit Charge HR to monitor physical activity, sleep and heart rate during IV therapy for pulmonary exacerbations
26. P347 A survey of cardiovascular disease in UK cystic fibrosis centres
27. P112 Proton pump inhibitor use is associated with increased pulmonary exacerbations and hospital admissions in adult patients with cystic fibrosis
28. P144 Changes in the lung microbiota in response to IV therapy for pulmonary exacerbations and relation to clinical outcomes
29. P141 Relationship between microbial load and rheological parameters in sputum from people with cystic fibrosis
30. P021 A phase 3, open-label study of tezacaftor/ivacaftor (TEZ/IVA) therapy: interim analysis of pooled safety, and efficacy in patients homozygous for F508del-CFTR
31. P097 Role of an exacerbation checklist score in the definition, assessment and outcome of cystic fibrosis pulmonary exacerbations
32. P079 The impact of non-antimicrobial therapies on bacterial pathogens commonly found in cystic fibrosis airways
33. P127 The role of the specialist cystic fibrosis pharmacist in embedding adherence monitoring of inhaled therapies into clinical care
34. P211 Prevalence of low BMD, osteoporosis and DEXA scan attendance in the North Ireland Adult CF Centre: the relationship to current guidelines
35. P162 The relationship of Cystic Fibrosis-Related Diabetes (CFRD) and abnormal lipid profiles in adults with cystic fibrosis
36. P191 Gender differences in lipid profiles in adults with cystic fibrosis
37. WS15.6 A phase 3, open-label study of tezacaftor/ivacaftor (TEZ/IVA) therapy: interim analysis of pooled safety, and efficacy in patients heterozygous for F508del-CFTR and a residual function mutation
38. 193 In vitro synergistic effect of NaCl and antibiotics against P. aeruginosa from cystic fibrosis patients
39. EPS1.3 Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: study design and rationale for the Rio-CF study
40. 149 Comparison of culture and quantitative PCR for bacterial quantification in CF sputum
41. IPD2.06 Development of a regional monitoring system for Inhaled Antibiotic collection as a measure of adherence
42. IPD2.04 Assessing the clinical impact of motivational interviewing on inhaled antibiotic (IA) adherence in CF
43. 217 An investigation into neutrophil elastase quantification using basic sputum processing techniques suitable for use in a clinical setting
44. 21 Lung function and disease severity in CF patients heterozygous for p. Arg117His
45. 139 Disease burden in patients (pts) with cystic fibrosis (CF) with at least one copy of the R117H (c.350G>A) mutation in the UK
46. 140 An evaluation of cystic fibrosis (CF)-related complications and treatment in patients (pts) with CF and at least one copy of the R117H (c.350G>A) mutation in the UK and the US
47. WS21.7 The relationship of maximum inspiratory pressures with inspiratory muscle weakness and FEV 1 in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa
48. 87 Detection of enterotoxins (A–E) from Staphylococcus aureus isolated from CF sputum: Clinical significance of enterotoxigenic (ET+) strains of S. aureus in paediatric and adult CF patients
49. 102 MRSA eradication in CF patients with lower respiratory tract infection
50. ePS03.5 Adherence monitoring in cystic fibrosis centres: Current practice and pharmacists’ perspectives
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.